Telesis Bio, Inc.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Baupost Group Llc/ma. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Baupost Group Llc/ma has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:VRTV / Veritiv Corp 10% Owner 0
US:GTX / Garrett Motion Inc. 10% Owner 26,570,589
US:TBIO / Telesis Bio, Inc. 10% Owner 0
US:VSAT / Viasat, Inc. 10% Owner 16,288,959
US:OREXQ / OREXIGEN THERAPEUTICS INC 10% Owner 0
US:KERX / Keryx Biopharmaceuticals, Inc. Director, 10% Owner 0
US:IDIX / Idenix Pharmaceuticals Inc 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Baupost Group Llc/ma. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TBIO / Telesis Bio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TBIO / Telesis Bio, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-06-26 TBIO BAUPOST GROUP LLC/MA 500,000 22.0000 27,778 396.0000 11,000,000 361 368.28 -770,286 -7.00

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TBIO / Telesis Bio, Inc. Insider Trades
Insider Sales TBIO / Telesis Bio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TBIO / Telesis Bio, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TBIO / Telesis Bio, Inc. Insider Trades
Insider Purchases VSAT / Viasat, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TBIO / Telesis Bio, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-07-23 VSAT BAUPOST GROUP LLC/MA 2,556,891 39.1100 2,556,891 39.1100 100,000,007 202 60.3200 54,231,658 54.23

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VSAT / Viasat, Inc. Insider Trades
Insider Sales VSAT / Viasat, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TBIO / Telesis Bio, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VSAT / Viasat, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Baupost Group Llc/ma as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-12-06 2023-11-30 4 VRTV Veritiv Corp
Common Stock
J - Other -3,324,324 0 -100.00 170.00 -565,135,080
2023-08-10 3 VRTV Veritiv Corp
Common Stock
3,324,324
2023-06-15 2023-06-15 4 GTX Garrett Motion Inc.
Common Stock
S - Sale -1,025,000 26,570,589 -3.71 7.55 -7,738,750 200,607,947
2023-06-15 2023-06-14 4 GTX Garrett Motion Inc.
Common Stock
S - Sale -3,100,000 27,595,589 -10.10 7.73 -23,963,000 213,313,903
2023-06-15 2023-06-13 4 GTX Garrett Motion Inc.
Common Stock
S - Sale -500,000 30,695,589 -1.60 8.00 -4,000,000 245,564,712
2023-06-15 2023-06-13 4 GTX Garrett Motion Inc.
Common Stock
C - Conversion 25,462,810 31,195,589 444.16
2023-06-12 2023-06-08 4 GTX Garrett Motion Inc.
Common Stock
S - Sale -500,000 3,075,000 -13.99 8.20 -4,100,000 25,215,000
2021-12-14 2021-12-10 4 GTX Garrett Motion Inc.
Series A Preferred Stock
S - Sale -1,827,868 25,480,292 -6.69 8.20 -14,988,518 208,938,394
2021-09-16 2021-09-14 4/A TBIO Translate Bio, Inc.
Common Stock
J - Other -18,044,239 0 -100.00 38.00 -685,681,082
2021-05-13 2021-05-11 4 GTX Garrett Motion Inc.
Series A Preferred Stock
S - Sale -761,905 27,308,160 -2.71
2021-05-11 2021-05-07 4 GTX Garrett Motion Inc.
Series A Preferred Stock
S - Sale -380,952 28,070,065 -1.34
2021-05-07 3 GTX Garrett Motion Inc.
Common Stock
3,575,000
2021-05-04 2021-04-30 4 GTX Garrett Motion Inc.
Common Stock
J - Other -3,575,000 0 -100.00
2020-10-23 3 GTX Garrett Motion Inc.
Common Stock
3,575,000
2020-07-27 2020-07-23 4 VSAT VIASAT INC
Common Stock
P - Purchase 2,556,891 16,288,959 18.62 39.11 100,000,007 637,061,186
2020-06-30 2020-06-26 4 TBIO Translate Bio, Inc.
Common Stock
P - Purchase 500,000 18,044,239 2.85 22.00 11,000,000 396,973,258
2019-09-20 3 TBIO Translate Bio, Inc.
Common Stock
35,088,478
2019-09-20 3 TBIO Translate Bio, Inc.
Common Stock
35,088,478
2019-09-20 3 TBIO Translate Bio, Inc.
Common Stock
35,088,478
2019-09-20 3 TBIO Translate Bio, Inc.
Common Stock
35,088,478
2019-09-20 3 TBIO Translate Bio, Inc.
Common Stock
35,088,478
2019-06-04 2019-05-31 4 OREXQ Orexigen Therapeutics, Inc.
0% Senior Secured Convertible Notes due 2020
J - Other 0
2019-06-04 2019-05-31 4 OREXQ Orexigen Therapeutics, Inc.
Warrant Expiring 2026
J - Other -100,000,000 0 -100.00
2019-06-04 2019-05-31 4 OREXQ Orexigen Therapeutics, Inc.
Warrant Expiring 2020
J - Other -5,000,000 0 -100.00
2018-12-13 2018-12-12 4 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -65,374,013 0 -100.00
2018-12-13 2018-12-11 4 KERX KERYX BIOPHARMACEUTICALS INC
Zero Coupon Senior Convertible Notes due 2021
M - Exercise 0
2018-12-13 2018-12-11 4 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
A - Award 4,000,000 65,374,013 6.52
2018-12-13 2018-12-11 4 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
A - Award 35,582,335 61,374,013 137.96 4.63 164,746,211 284,161,680
2018-10-31 2018-10-31 4 OREXQ Orexigen Therapeutics, Inc.
Common Stock
S - Sale -896,339 0 -100.00 0.01 -8,963
2018-10-31 2018-10-29 4 OREXQ Orexigen Therapeutics, Inc.
Common Stock
S - Sale -650,000 896,339 -42.03 0.01 -6,500 8,963
2018-10-26 2018-10-25 4 OREXQ Orexigen Therapeutics, Inc.
Common Stock
S - Sale -652,500 1,546,339 -29.67 0.01 -6,525 15,463
2018-10-26 2018-10-24 4 OREXQ Orexigen Therapeutics, Inc.
Common Stock
S - Sale -28,000 2,198,839 -1.26 0.01 -280 21,988
2018-10-04 3 VSAT VIASAT INC
$0.0001 par value common stock
27,464,136
2018-10-04 3 VSAT VIASAT INC
$0.0001 par value common stock
27,464,136
2018-10-04 3 VSAT VIASAT INC
$0.0001 par value common stock
27,464,136
2018-10-04 3 VSAT VIASAT INC
$0.0001 par value common stock
27,464,136
2018-10-04 3 VSAT VIASAT INC
$0.0001 par value common stock
27,464,136
2018-05-10 2018-05-08 4 KERX KERYX BIOPHARMACEUTICALS INC
Zero Coupon Senior Convertible Notes due 2021
A - Award
2018-05-10 2018-05-08 4 KERX KERYX BIOPHARMACEUTICALS INC
Zero Coupon Convertible Senior Notes due 2020
D - Sale to Issuer 0 125,000,000.00
2018-04-26 2018-04-13 4 OREX Orexigen Therapeutics, Inc.
0% Senior Secured Convertible Notes due 2020
J - Other -16,483,517 7,802,197 -67.87
2016-03-24 3 OREX Orexigen Therapeutics, Inc.
Common Stock
44,536,798
2016-03-24 3 OREX Orexigen Therapeutics, Inc.
Common Stock
44,536,798
2016-03-24 3 OREX Orexigen Therapeutics, Inc.
Common Stock
44,536,798
2016-03-24 3 OREX Orexigen Therapeutics, Inc.
Common Stock
44,536,798
2015-10-20 3 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
84,032,552
2015-10-20 3 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
84,032,552
2015-10-20 3 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
84,032,552
2015-10-20 3 KERX KERYX BIOPHARMACEUTICALS INC
Common Stock
84,032,552
2014-08-12 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Common Stock
J - Other -53,331,109 0 -100.00 24.50 -1,306,612,170
2014-02-04 2014-01-31 4 IDIX IDENIX PHARMACEUTICALS INC
Common Stock
P - Purchase 16,420,241 53,331,109 44.49 6.50 106,731,566 346,652,208
2013-11-01 3 IDIX IDENIX PHARMACEUTICALS INC
Idenix Pharmaceuticals, inc.
36,910,868
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)